nach oben

Journal of Hepato-Biliary-Pancreatic Sciences

Erschienen in:

01.05.2010 | Topics

Tumorigenesis and phenotypic characteristics of mucin-producing bile duct tumors: an immunohistochemical approach

verfasst von: Yasuni Nakanuma, Yoh Zen, Kenichi Harada, Hiroko Ikeda, Yasunori Sato, Takeshi Uehara, Motoko Sasaki

Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Intraductal papillary neoplasm of the bile duct (IPNB) is characterized by exophytic proliferation of neoplastic epithelial cells with fibrovascular stalks in bile duct lumen, mucin hypersecretion, and considerable dilatation or multilocular changes of the affected bile ducts. A mucin-producing bile duct tumor is an IPNB with excessive mucin production and clinical symptoms. Herein, the phenotypes as well as the tumorigenesis and progression of IPNB are reviewed with immunohistochemical assistance. The tumors are subdivided into three phenotypes: pancreatobiliary, intestinal, and gastric. About half of IPNB cases are of the pancreatobiliary type, and the remaining half are of the intestinal type. Aberrant expression of CDX2 with MUC2 and CK20 is related to the development of intestinal metaplasia. Inactivation of P16INK4a and nuclear expression of β-catenin are related to the development of IPNB. Decreased expression of membranous β-catenin and E-cadherin and aberrant expression of MMP-7 and -9 and of MUC1 are related to invasion of IPNB with tubular adenocarcinoma, whereas MUC2 is involved in the invasion of IPNB with mucinous carcinoma. IPNB can be regarded as a counterpart of intraductal papillary mucinous neoplasm (IPMN) of the pancreas, particularly the main duct type. More comparative studies between IPNB and pancreatic IPMN are recommended for further analysis of these papillary neoplasms.

Wheeler DA, Edmondson HA. Cystadenoma with mesenchymal stroma (CMS) in the liver and bile ducts. A clinicopathologic study of 17 cases, 4 with malignant change. Cancer. 1985;56:1434–45.CrossRefPubMed

Devaney K, Goodman ZD, Ishak KG. Hepatobiliary cystadenoma and cystadenocarcinoma. A light microscopic and immunohistochemical study of 70 patients. Am J Surg Pathol. 1994;18:1078–91.PubMedCrossRef

Sakamoto E, Hayakawa N, Kamiya J, Kondo S, Nagino M, Kanai M, et al. Treatment strategy for mucin-producing intrahepatic cholangiocarcinoma: value of percutaneous transhepatic biliary drainage and cholangioscopy. World J Surg. 1999;23:1038–43.CrossRefPubMed

Goto M, Shibahara H, Tamada S, Hamada T, Oda K, Nagino M, et al. Aberrant expression of pyloric gland-type mucin in mucin-producing bile duct carcinomas: a clear difference between the core peptide and the carbohydrate moiety. Pathol Int. 2005;55:464–70.CrossRefPubMed

Longnecker DS, Hruban RH, Adler G, Kloppel G. Intraductal papillary-mucinous neoplasms of the pancreas. In: Hamilton SR, Aaltonen LA, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. p. 237–40.

Zamboni G, Longnecker DS, Kloppel G, Adler G, Hruban RH. Mucinous cystic neoplasm of the pancreas. In: Hamilton SR, Aaltonen LA, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. p. 234–6.

Chen TC, Nakanuma Y, Zen Y, Chen MF, Jan YY, Yeh TS, et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology. 2001;34:651–8.CrossRefPubMed

Zen Y, Fujii T, Itatsu K, Nakamura K, Minato H, Kasashima S, et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology. 2006;44:1333–43.CrossRefPubMed

Abraham SC, Lee JH, Hruban RH, Argani P, Furth EE, Wu TT. Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract. Hum Pathol. 2003;34:902–10.CrossRefPubMed

10.

Nakanuma Y, Leong ASY, Sripa B, Ponchon T, Vatanasapt V, Ishak KG. Intrahepatic cholangiocarcinoma. In: Hamilton SR, Aaltonen LA, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. p. 173–80.

11.

Nakanuma Y, Sasaki M, Ishikawa A, Tsui W, Chen TC, Huang SF. Biliary papillary neoplasm of the liver. Histol Histopathol. 2002;17:851–61.PubMed

12.

Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment. J Gastroenterol Hepatol. 2002;17:1056–63.CrossRefPubMed

13.

Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg. 2005;241:703–12.CrossRefPubMed

14.

Adbores-Saavedra J, Scoazec JC, Wittekind C, Sripa B, Menck HR, Soehendra N. Carcinoma of the gallbladder and extrahepatic bile ducts. In: Hamilton SR, Aaltonen LA, et al., editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. p. 207–14.

15.

Albores-Saavedra J, Murakata L, Krueger JE, Henson DE. Noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts. Cancer. 2000;89:508–15.CrossRefPubMed

16.

Young TH, Chen TK, Lee HS. Electronic clinical challenges and images in GI. Noninvasive and minimally invasive papillary carcinomas of the common bile duct. Gastroenterology. 2008;134:e1–3.CrossRefPubMed

17.

Lee SS, Kim MH, Lee SK, Jang SJ, Song MH, Kim KP, et al. Clinicopathologic review of 58 patients with biliary papillomatosis. Cancer. 2004;100:783–93.CrossRefPubMed

18.

Nakanuma Y, Hoso M, Sanzen T, Sasaki M. Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply. Microsc Res Tech. 1997;38:552–70.CrossRefPubMed

19.

Nakanishi Y, Zen Y, Kondo S, Itoh T, Itatsu K, Nakanuma Y. Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm. Hum Pathol. 2008;39:1153–61.CrossRefPubMed

20.

Itatsu K, Zen Y, Ohira S, Ishikawa A, Sato Y, Harada K, et al. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis. Liver Int. 2007;27:1174–84.PubMed

21.

Zen Y, Fujii T, Itatsu K, Nakamura K, Konishi F, Masuda S, et al. Biliary cystic tumors with bile duct communication: a cystic variant of intraductal papillary neoplasm of the bile duct. Mod Pathol. 2006;19:1243–54.CrossRefPubMed

22.

Sudo Y, Harada K, Tsuneyama K, Katayanagi K, Zen Y, Nakanuma Y. Oncocytic biliary cystadenocarcinoma is a form of intraductal oncocytic papillary neoplasm of the liver. Mod Pathol. 2001;14:1304–9.CrossRefPubMed

23.

24.

Sasaki M, Ikeda H, Nakanuma Y. Expression profiles of MUC mucins and trefoil factor family (TFF) peptides in the intrahepatic biliary system: physiological distribution and pathological significance. Prog Histochem Cytochem. 2007;42:61–110.CrossRefPubMed

25.

Sasaki M, Yamaguchi J, Itatsu K, Ikeda H, Nakanuma Y. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol. 2008;215:175–83.CrossRefPubMed

26.

Ishikawa A, Sasaki M, Ohira S, Ohta T, Oda K, Nimura Y, et al. Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2 expression in intraductal papillary neoplasm of the liver in hepatolithiasis. Lab Invest. 2004;84:629–38.CrossRefPubMed

27.

Sasaki M, Tsuneyama K, Saito T, Kataoka H, Mollenhauer J, Poustka A, et al. Site-characteristic expression and induction of trefoil factor family 1, 2 and 3 and malignant brain tumor-1 in normal and diseased intrahepatic bile ducts relates to biliary pathophysiology. Liver Int. 2004;24:29–37.CrossRefPubMed

28.

Ban S, Naitoh Y, Mino-Kenudson M, Sakurai T, Kuroda M, Koyama I, et al. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types. Am J Surg Pathol. 2006;30:1561–9.CrossRefPubMed

29.

Terada T, Nakanuma Y, Kakita A. Pathologic observations of intrahepatic peribiliary glands in 1,000 consecutive autopsy livers. Heterotopic pancreas in the liver. Gastroenterology. 1990;98:1333–7.PubMed

30.

Terada T, Nakanuma Y. Development of human intrahepatic peribiliary glands. Histological, keratin immunohistochemical, and mucus histochemical analyses. Lab Invest. 1993;68:261–9.PubMed

31.

Terada T, Nakanuma Y. Expression of pancreatic enzymes (alpha-amylase, trypsinogen, and lipase) during human liver development and maturation. Gastroenterology. 1995;108:1236–45.CrossRefPubMed

32.

Dumas A, Thung SN, Lin CS. Diffuse hyperplasia of the peribiliary glands. Arch Pathol Lab Med. 1998;122:87–9.PubMed

33.

Nakanuma Y, Sasaki M, Terada T, Harada K. Intrahepatic peribiliary glands of humans. II. Pathological spectrum. J Gastroenterol Hepatol. 1994;9:80–6.CrossRefPubMed

34.

Terada T, Nakanuma Y. Pathologic observations of intrahepatic peribiliary glands in 1,000 consecutive autopsy livers: IV. Hyperplasia of intramural and extramural glands. Hum Pathol. 1992;23:483–90.CrossRefPubMed

35.

Zen Y, Sasaki M, Fujii T, Chen TC, Chen MF, Yeh TS, et al. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct—an immunohistochemical study of 110 cases of hepatolithiasis. J. Hepatol. 2006;44:350–8.CrossRefPubMed

36.

Zen Y, Adsay NV, Bardadin K, Colombari R, Ferrell L, Haga H, et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol. 2007;20:701–9.CrossRefPubMed

37.

Itatsu K, Fujii T, Sasaki M, Zen Y, Nakanuma Y. Intraductal papillary cholangiocarcinoma and atypical biliary epithelial lesions confused with intrabiliary extension of metastatic colorectal carcinoma. Hepatogastroenterology. 2007;54:677–80.PubMed

38.

Ishikawa A, Sasaki M, Sato Y, Ohira S, Chen MF, Huang SF, et al. Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis. Hum Pathol. 2004;35:1505–14.CrossRefPubMed

39.

Momoi H, Itoh T, Nozaki Y, Arima Y, Okabe H, Satoh S, et al. Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma. J Hepatol. 2001;35:235–44.CrossRefPubMed

40.

He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509–12.CrossRefPubMed

41.

Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M, et al. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol. 2005;27:973–80.PubMed

42.

Doucas H, Garcea G, Neal CP, Manson MM, Berry DP. Change in the Wnt signaling pathway in gastrointestinal cancers and their prognostic significance. Eur J Cancer. 2005;41:365–79.CrossRefPubMed

43.

DeHaan RD, Kipp BR, Smyrk TC, Abraham SC, Roberts LR, Halling KC. An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. Hum Pathol. 2007;38:491–9.CrossRefPubMed

44.

Abraham SC, Lee JH, Boitnott JK, Argani P, Furth EE, Wu TT. Microsatellite instability in intraductal papillary neoplasms of the biliary tract. Mod Pathol. 2002;15:1309–17.CrossRefPubMed

45.

Amaya S, Sasaki M, Watanabe Y, Tsui WM, Tsuneyama K, Harada K, et al. Expression of MUC1 and MUC2 and carbohydrate antigen Tn change during malignant transformation of biliary papillomatosis. Histopathology. 2001;38:550–60.CrossRefPubMed

46.

Sasaki M, Nakanuma Y, Kim YS. Characterization of apomucin expression in intrahepatic cholangiocarcinomas and their precursor lesions: an immunohistochemical study. Hepatology. 1996;24:1074–8.CrossRefPubMed

47.

Adsay NV, Merati K, Andea A, Sarkar F, Hruban RH, Wilentz RE, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol. 2002;15:1087–95.CrossRefPubMed

48.

Ashida K, Terada T, Kitamura Y, Kaibara N. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology. 1998;27:974–82.CrossRefPubMed

49.

Zheng Z, Pan J, Chu B, Wong YC, Cheung AL, Tsao SW. Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum Pathol. 1999;30:458–66.CrossRefPubMed

50.

Terada T, Okada Y, Nakanuma Y. Expression of immunoreactive matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology. 1996;23:1341–4.CrossRefPubMed

51.

Miwa S, Miyagawa S, Soeda J, Kawasaki S. Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma. Cancer. 2002;94:428–34.CrossRefPubMed

52.

Sato M, Watanabe Y, Tokui K, Kohtani T, Nakata Y, Chen Y, et al. Hepatobiliary cystadenocarcinoma connected to the hepatic duct: a case report and review of the literature. Hepatogastroenterology. 2003;50:1621–4.PubMed

53.

Portman BC, Nakanuma Y. Diseases of bile ducts. In: Burt AD, Portman BC, Ferrell LD, editors. MacSween’s pathology of the liver. 5.th ed. London: Churchill Livingstone; 2006. p. 517–81.

54.

Terada T, Nakanuma Y. Pathological observations of intrahepatic peribiliary glands in 1,000 consecutive autopsy livers. II. A possible source of cholangiocarcinoma. Hepatology. 1990;12:92–7.CrossRefPubMed

55.

Zen Y, Terahata S, Miyayama S, Mitsui T, Takehara A, Miura S, et al. Multicystic biliary hamartoma: a hitherto undescribed lesion. Hum Pathol. 2006;37:339–44.CrossRefPubMed

56.

Fujii T, Harada K, Katayanagi K, Kurumaya H, Nakanuma Y. Intrahepatic cholangiocarcinoma with multicystic, mucinous appearance and oncocytic change. Pathol Int. 2005;55:206–9.CrossRefPubMed

Titel: Tumorigenesis and phenotypic characteristics of mucin-producing bile duct tumors: an immunohistochemical approach
verfasst von: Yasuni Nakanuma
Yoh Zen
Kenichi Harada
Hiroko Ikeda
Yasunori Sato
Takeshi Uehara
Motoko Sasaki
Publikationsdatum: 01.05.2010
Verlag: Springer Japan
Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences / Ausgabe 3/2010
Print ISSN: 1868-6974
Elektronische ISSN: 1868-6982
DOI: https://doi.org/10.1007/s00534-009-0158-7

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Laparoscopic liver surgery: 8 years of multicenter Spanish register

Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system

Endoscopic diagnosis of intraductal papillary mucinous neoplasm of the bile duct

Is 18F-fluorodeoxyglucose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis?

Mucin-producing bile duct tumors: radiological–pathological correlation and diagnostic strategy

Risk factors for postoperative pancreatic fistula after pancreaticoduodenectomy: the significance of the ratio of the main pancreatic duct to the pancreas body as a predictor of leakage

Update Chirurgie